Xenon Pharmaceuticals
XENE
Xenon Pharmaceuticals (XENE) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$1.11
- EPS estimate
- −$1.14
- EPS surprise
- +2.76%
- Revenue surprise
- −100.00%
- Revenue
- $0.00
- Revenue estimate
- $1.7M
- Reported
- Aug 6, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | −$1.14 | −$1.11 | +2.76% | $0.00 | SEC |
| Q1 2026 | May 7, 2026 | −$1.18 | −$1.17 | +0.81% | $0.00 | SEC |
| Q3 2025 | Nov 3, 2025 | −$1.15 | −$1.15 | +0.21% | $0.00 | SEC |
| Q2 2025 | Aug 11, 2025 | −$0.99 | −$1.07 | −8.37% | $0.00 | SEC |
| Q1 2025 | May 12, 2025 | −$0.90 | −$0.83 | +7.39% | $7.5M | SEC |
| Q4 2024 | Feb 27, 2025 | −$0.86 | −$0.84 | +2.38% | $0.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.82 | −$0.81 | +0.69% | $0.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.70 | −$0.75 | −7.11% | $0.00 | SEC |
| Q1 2024 | May 9, 2024 | −$0.66 | −$0.62 | +6.65% | $0.00 | SEC |
| Q4 2023 | Feb 29, 2024 | −$0.76 | −$0.64 | +15.70% | $0.00 | SEC |
| Q3 2023 | Nov 8, 2023 | −$0.77 | −$0.73 | +5.68% | $0.00 | SEC |
| Q2 2023 | Aug 9, 2023 | −$0.70 | −$0.72 | −3.36% | $0.00 | SEC |
| Q1 2023 | May 9, 2023 | −$0.62 | −$0.63 | −1.45% | $0.00 | SEC |
| Q4 2022 | Mar 1, 2023 | −$0.58 | −$0.57 | +2.55% | $0.00 | SEC |
| Q3 2022 | Nov 8, 2022 | −$0.52 | −$0.57 | −9.62% | $132,000.00 | SEC |
| Q2 2022 | Aug 9, 2022 | −$0.48 | −$0.55 | −13.87% | $536,000.00 | SEC |
| Q1 2022 | May 10, 2022 | −$0.41 | −$0.35 | +13.71% | $8.8M | SEC |
| Q4 2021 | Mar 1, 2022 | −$0.37 | −$0.48 | −29.35% | $3.7M | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.38 | −$0.36 | +6.08% | $8.1M | SEC |
| Q2 2021 | Aug 11, 2021 | −$0.48 | −$0.51 | −6.52% | $2.2M | SEC |
Quarterly revenue
Frequently asked questions
When did Xenon Pharmaceuticals (XENE) last report earnings?
Xenon Pharmaceuticals last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did XENE beat earnings estimates?
Yes. Xenon Pharmaceuticals reported EPS of −$1.11 for Q2 2026 against a −$1.14 estimate — a 2.76% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.